3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow betrixaban: new trials by email Literature Review of betrixaban trials Research Report on betrixaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV) - Bleeding | Phase 2 | Terminated | Portola Pharmaceuticals | 18 | 2015-08-06 | 2023-08-08 |
| Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Amiodarone, Betrixaban 60 mg, Betrixaban 90 mg - Atrial Fibrillation, Atrial Flutter | Phase 2 | Completed | Portola Pharmaceuticals | 189 | 2010-09-01 | 2023-08-07 |
| Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin betrixaban, Warfarin - Atrial Fibrillation | Phase 2 | Completed | Portola Pharmaceuticals | 508 | 2008-10-01 | 2023-08-07 |
| Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) Betrixaban, Enoxaparin - Thromboembolism | Phase 2 | Completed | Portola Pharmaceuticals | 215 | 2006-05-01 | 2023-08-07 |
Atrial Fibrillation (2) · Atrial Flutter (1) · Hemorrhage (1) · Thromboembolism (1)
Canada (2) · United States (2)
Michael Ezekowitz, MD, PhD, (1) · Paul Dorian, MD (1) · Rafael Diaz, MD (1) · Stefan H. Hohnloser, MD (1) · Stuart Connolly, MD, FRCP (1)